Docetaxel + 5 fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 7, 2005, Pages 380-385

  Oh, Do Youn ^a   Kim, Tae Yong ^a   Kwon, Jung Hye ^a   Lee, Jae Jin ^a   Joh, Yohan ^a   Kim, Dong Wan ^a   Kim, Tae You ^a   Heo, Dae Seog ^a   Bang, Yung Jue ^a   Kim, Noe Kyeong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Chemotherapy; Cisplatin; Docetaxel; Gastric cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; HUMAN; INOPERABLE CANCER; LEUKOPENIA; MALE; MOUTH LESION; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 24944592562     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi107     Document Type: Article

References (23)

1. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15:57-77.
2. Pyrhonen S, Kuitunen T, Nsyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
4. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71: 3813-8.
5. Ajani JA, Van Cutsem E, Moiseyenko V, Yjulandin S, Fodor M, et al. Docetaxel, cisplatin, 5-fluorouracil compared to cisplatin and 5-fluorouracil for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma: Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;22:249 (abstr 999).
6. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227-31.
7. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/ II trial. J Clin Oncol 1998;16:1331-9.
8. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-11.
9. Janinis J, Panagos G. Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer. J Clin Oncol 2000;18: 1393-5.
10. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-104.
11. Tanaka M, Obata T, Sasaki T. Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancer in vitro and in vivo. Eur J Cancer 1996;32A:226-30.
12. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: A phase II trial. Jpn J Clin Oncol 2002;32:248-54.
13. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel in advanced gastric cancer: Results of a phase II clinical trial. Br J Cancer 1994;70:380-3.
14. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial. Am J Clin Oncol 2000;23:341-4.
15. Wilke H, Vanhoefer U, Harstrick A, Achterrath W, Preusser PW, Clemens MR, et al. Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998;17:305 (abstr 1177).
16. Furue H, Taguchi T. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer. Ann Oncol 1998; 9 (Supp14):233p (abstr).
17. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
18. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Taxotere-cisplatin in advanced gastric carcinoma: An active drug combination. Ann Oncol 2000;11:301-6.
19. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Docetaxel and cisplatin combination therapy for advanced gastric cancer: results of two phase II studies. Proc Am Soc Oncol 2001;20:165.
20. Roth AD, Maibach R, Fazio N, et al. 5-FU as protracted continuous i.v. infusion can be added to full dose taxotere-cisplatin in advanced gastric carcinoma (AGC). Eur J Cancer 1999;35 (Suppl 4): S139.
21. Ajani JA, Fodor M, Van Cutsem E, et al. Multinational randomized phase II trial of docetaxel and cisplatin with or without 5-fluorouracil inpatients with advanced gastric cancer or GE junction adenocarcinoma. Proc Am Soc Oncol 2000;19:247.
22. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003; 14 (Suppl 2):iI41-4.
23. Roth AD, Maibach R, Falk S, Stupp R, Saletti P, et al. Docetaxel-cisplatin-5FU versus docetaxel-cisplatin versus epirubicin-cisplatin-5FU as systemic treatment for advanced gastric cancer: A randomized phase III trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2004;22:14S (abstr 4020).